Physician Sentiment on CARVYKTI®

Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated 2026-07-13. KOL Pulse reports the physician conversation and does not endorse any product.

Trial 1 · NCT04181827

What do oncologists think of the CARTITUDE-4 trial (CARVYKTI®)?

CARTITUDE-4 — Earlier-line relapsed/refractory multiple myeloma (single cilta-cel infusion vs standard triplet regimens; 1–3 prior lines, lenalidomide-refractory)

FDA APPROVED · Apr 2024 · earlier-lineCARVYKTI® (ciltacabtagene autoleucel) is FDA-approved (April 5, 2024) for adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent and are refractory to lenalidomide — the earlier-line expansion, based on CARTITUDE-4.

Physicians are genuinely mixed on CARTITUDE-4: 22% of 46 verified physician voices positive, 24% nuanced (praising the result while flagging a caveat), 45% neutral, 9% critical.

22%

24%

45%

Positive 22% Nuanced 24% Neutral 45% Critical 9%

Denominator: 46 distinct verified physician voices across 224 oncologist posts, 2023-02-10 to 2026-05-29. Sponsor: Janssen Research & Development (with Legend Biotech)

See full CARTITUDE-4 conference coverage & trial data →

Primary sources: ClinicalTrials.gov · NCT04181827 · FDA Approval Summary — CARVYKTI earlier-line R/R MM (Apr 2024)

FDA approval (April 5, 2024): ciltacabtagene autoleucel (CARVYKTI) for adults with relapsed or refractory multiple myeloma after at least one prior line including a PI and an IMiD and refractory to lenalidomide (based on CARTITUDE-4, NCT04181827).

Physician voices — verbatim

Representative positive voice

👀 OS data from CARTITUDE-4 (cilta-cel CAR-T versus #MMsm standard therapies in 1-3 lines). This is WONDERFUL to see!! Looking forward to hearing the ODAC meeting later this week... and no doubt the manuscript that is in preparation!

Rahul Banerjee, MD, FACP

@RahulBanerjeeMD

Representative nuanced voice

Breaking: ODAC votes 11-0 to recommend approval of ciltacel in patients with relapsed/refractory multiple myeloma in earlier stages. I’m glad. Right call. But we need to be careful. Read on.

Vincent Rajkumar

@VincentRK

Representative critical voice

CARTITUDE-4 risk of secondary hematologic malignancies is very concerning. I am becoming increasingly concerned about this CART being used in the frontline (and god forbid) smoldering setting Also Parkinsonism and cranial nerve palsies are quality of life destroyers.

Aaron Goodman - “Papa Heme”

@AaronGoodman33

Full physician voice list (46)

Physician	Comment (verbatim)	Sentiment	Impressions
Samer Al Hadidi, MD,MS,FACP @HadidiSamer	#mmsm How to counsel patients about Cilta Cel using the data from CARTITUDE-4 and FDA ODAC meeting for earlier use With data of Cilta cel and Ide cel, assuming having access to both for a given patient, I will personally chose Cilta cel (…	Neutral	51,278
Aaron Goodman - “Papa Heme” @AaronGoodman33	CARTITUDE-4 risk of secondary hematologic malignancies is very concerning. I am becoming increasingly concerned about this CART being used in the frontline (and god forbid) smoldering setting Also Parkinsonism and cranial nerve palsies ar…	Negative	34,940
Vinay Prasad MD MPH @VPrasadMDMPH	Car T is officially a hematopoietic carcinogen. If the trial control arm was ethical it would include Kpd and DKd and it might be a negative trial.	Negative	30,954
Rahul Banerjee, MD, FACP @RahulBanerjeeMD	👀 OS data from CARTITUDE-4 (cilta-cel CAR-T versus #MMsm standard therapies in 1-3 lines). This is WONDERFUL to see!! Looking forward to hearing the ODAC meeting later this week... and no doubt the manuscript that is in preparation!	Positive	29,493
Vincent Rajkumar @VincentRK	Breaking: ODAC votes 11-0 to recommend approval of ciltacel in patients with relapsed/refractory multiple myeloma in earlier stages. I’m glad. Right call. But we need to be careful. Read on.	Nuanced	26,296
Taxiarchis Kourelis @Taxkourel	Vincent this would be a great Monday meeting discussion. Here are my points of confusion 1) Ciltacel 2nd line in Dara naive makes me pause. here is the OS curve for 2nd line patients with Ciltacel (source https://t.co/WiL1IPdtAH). Tec-Dara …	Nuanced	9,868
Irene Ghobrial @IrenemGhobrial	Excited to share results of Ciltacel in high risk SMM. @OmarNadeemMD #aacr2026 plenary presentation. @NatureMedicine publication. Thank you to our patients! #mmsm	Positive	8,616
Raj Chakraborty @rajshekharucms	With 85% CD38-refractory, we are seeing at least a similar (if not better) PFS with single-agent Teclistamab when compared to Cilta-cel arm of CARTITUDE-4, which had just ~25% CD38-refractory. These results, along with MajesTEC-3, challenge…	Neutral	8,216
Ben Derman @bdermanmd	FDA focused on increased early risk of death, but the diff. between discussion on ide-cel vs cilta-cel is that with crossover to ide-cel, access to ide-cel later on made up for lack of receipt earlier. This is not an argument about yes/no …	Nuanced	5,939
Luciano J Costa @End_myeloma	We had the privilege to contribute to both Cartitude-4 and KarMMa-3. Crucial differences between these important studies often overlooked #myeloma 1/X	Positive	5,703
Henry C Fung\| MM, lymphoma, leukemia & CART @henrychihangfu1	MajesTec - 9 & MajecTec - 3 & Cartitude - 4 - My interpretations. IMO: the real question is no longer Tec vs CAR-T. The real question is: which patient should receive which immunotherapy, and when? MajesTEC-9, CARTITUDE-4, and CARTITUDE…	Nuanced	5,371
Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD	2 CAR-T got approved for myeloma; Cilta-Cel after 1 Line & Ide-Cel after 2nd Line; it will be interested to see how we will proceed in RW 🤔 More importantly, Did @FDAOncology decide to punish @bmsnews due to allowing crossover in KARMMA-3? …	Neutral	5,365
Murali Janakiram @JanakiramMurali	We can agree that ciltacel is an active drug and better than SOC in 1-3 LOT setting We need to do better in the bridging space. - The goal of bridging is to get as minimal disease as feasible after leukapheresis - Why lower disease volume…	Neutral	4,323
Susan Bal @SusanBal9	Excellent thread on cilta-cel, only point I would highlight is if you progress on bridging therapy, your risk of fatal outcome 🔝 and in that situation I would not proceed directly with cilta cel but consider other options to lower disease b…	Nuanced	3,648
Malin Hultcrantz MD PhD @MalinHultcrantz	FDA Approves Cilta-Cel for R/R Multiple Myeloma Who Have Received at Least One Prior Line of Therapy and Are Refractory to Lenalidomide #mmsm	Neutral	2,615
Manni Mohyuddin @ManniMD1	We are all tempted to compare to cilta-cel. The CARTITUDE-4 trial is positive on a press-release, but please remember, the patient population in that trial will be less heavily pre-treated (1-3 lines is enrollment criteria)- so not fair t…	Nuanced	2,388
Craig Cole @CraigEmmittCole	I Agee that the FDA ODAC committee voting in favor of benefit-risk of Cilta-Cel in early R/R Myeloma is fantastic, but it means that we really need to make this equitable to myeloma patients regardless of income, race, ethnicity, or access …	Positive	2,364
Gareth Morgan @DrGarethMorgan1	This is very encouraging Rahul I guess the question is will the curve stay stable or will it decay like the SoC arm. @RahulBanerjeeMD	Neutral	1,644
Mike Thompson, MD, PhD, FASCO @mtmdphd	Earlier cilta-cel assoc w/ better immune fitness & stronger immune effects - correlative analysis of PB & BM tumor microenvironment (TME) from CARTITUDE-4 study [Nov 3, 2025] Parekh et al. #ASH25 abs25-8211 PID 92 https://t.co/pJwTOWV5BL #m…	Neutral	1,642
Ashley Aaroe, MD @AshleyAaroe	On the med onc side do you think there is an appreciation that mechanistically this kind of neurotoxicity is unlikely to be very treatable? I personally don't expect this to respond well to immunosuppression. Or to dopaminergic therapy, fr…	Negative	1,299
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1	provided data on OS for CARTITUDE 4. Also maintains PFS advantage. No new cases of MNT or cranial nerve palsies. High rate of MRD- #IMS24RF #mmsm	Neutral	1,249
nizar jacques bahlis @NBahlis	ODAC Casts 11 to 0 Vote in Favor of Cilta-Cel in R/R Multiple Myeloma	Positive	1,211
Joshua Richter, MD, FACP @JoshuaRichterMD	I didn’t hear all of the commentary but to me the big issue will be the words of the fda label. Cartitude-4 was 1-3 priors and karmma-3 was 2-4. Will the fda homogenize the labels or will carvykti be 2nd line and abecma only 3 plus.	Nuanced	1,115
Oncology Brothers @OncBrothers	8. #CARTITUDE4: Ph 3, Cilta-cel vs SoC for Len refractory MM after 1-3L: - At 33.6mos, MRD 63% vs 18% - CART will be an option for a small high risk pt at 1st R/R settings. - MRD is not still SoC to make treatment decisions 9/10 https:/…	Neutral	813
Santhosh Ambika @RenoHemonc	HRMM progressing after frontline D-RVd . All options accessible, after ODAC data -you will choose @AaronGoodman33 @HadidiSamer @rajshekharucms @RahulBanerjeeMD @End_myeloma @MyelomaSLC @myeloma	Neutral	756
Carlos E. Vigil, MD,FACP @cvigilgonzales	I agree on your concerns. Side effects on this product had been a characteristic that is difficult to ignore. I acknowledge the improve PFS but these side effects are significant.	Nuanced	633
Joe Bennett MD @JOEBENNETTMD	Riveting journal club on CARTITUDE-4: 12mo PFS 76% vs 49%, HR 0.26, TRAE discussion continues COVID infections, secondary malignancies, CAR-T after >= 1 line / 2 lines? Myeloma landscape is changing. @Abdallah81MD @MaireOkoniewski @leshune …	Neutral	625
Andrew Rezvani @AndrewRezvani	Implying melohalan is to blame for the excess sMDS/AML in the cilta-cel arm, even though melphalan esposure was if anything higher in the SoC arm… 🤔	Nuanced	435
M. Bolton @5_utr	CARTITUDE trial conclusion can only really be expressed as https://t.co/5fDm58Vh58	Neutral	422
Dr Amol Akhade @SuyogCancer	Thanks for this data. At 5 years , Out of 74 pts ,median OS is 55 months and 18 % ( 13 pts ) were disease free . Rest 61 patient' unfortunately could not sustain the benifit. As per authors , patients who are less heavily pre treated …	Negative	357
Elias K. Mai MD @EliasKarlMai	this benefit is driven by inequality in the treatment of patients in the control arm…I‘d rather have no OS benefit but crossover after PD. We should aim to improve this for our patients with #MMsm	Nuanced	349
Jordan Gauthier @drjgauthier	General method question: how do you handle patients who stop being MRD-tested? Censor?	Neutral	332
Andrew Portuguese @AJPortuguese	Censoring strategies would likely be informative because MRD-pos patients with PD or stable, quantifiable M-spikes may not be checked for MRD. This would inflate MRD-neg rates. Cumulative incidence of MRD-neg might provide a more accurate p…	Nuanced	299
Amar Kelkar, MD, MPH, FACP @amarkelkar	Totally agree re:sequencing based on the KarMMa-3 and CARTITUDE-4 data from ODAC. For KarMMa-3/Ide-cel I think it’s clear that it’s not worse to wait on using CAR to a later line. And with the lack of crossover for CARTITUDE-4/Cilta-cel it’…	Neutral	212
Alex Rampotas @ARampotas	Very shallow approach to this issue. CAR-Ts for myeloma have been proven to have efficacy. Even taking the small risk of secondary cancers into account, they likely have a significant overall survival benefit.	Positive	209
Yi Lin @YiLinMDPhD	Great job @Kennethjclim presenting @MayoCancerCare risk factor of IEC-nerve palsy & Parkinsonism #EHA25 #mmsm Hopefully we will learn soon from CARTITUDE trials & RWE across centers whether additional early mitigating strategies could redu…	Positive	208
Marc Braunstein, MD, PhD, FACP @docbraunstein	Cilta cel approved after one line of therapy for #myeloma	Neutral	161
Michael H. Tomasson, MD @MTomasson	Great data! Full disclosure: I did not enroll patients onto CARTITUDE 4 because the control arm was less than ideal triplet therapy. So as good as they are, these data will not change my practice	Positive	158
Andrew Yee, MD @andrew02114	Link to FDA documents for cilta-cel and ide-cel here (lots of data and food for thought) https://t.co/oLQEqVXwPG. .	Neutral	145
Jim Omel @IMFjimMYELOMA	Cilta-cel Maintains Survival Benefit in Lenalidomide-Refractory Multiple Myeloma https://t.co/OcBMzEOUL0 via @onclive	Neutral	145
Parva Bhatt @pbhattMD	Excellent thread on how to talk to patients about cilta cel…I have certainly thought about this a lot. Thank you for posting!	Positive	120
Hamza Hashmi @hhashmi87	Oral Abstract @End_myeloma: 30m fu of CART-4 standard risk myeloma and c/w CART-1. 20% CD38 refractory in CAR T-4, , 2 vs 6 pLOT, Better PFS (80% vs 60%) and no Parkinsonism w early use of CAR T. Is CAR T as good as Dara Tec for SR myeloma …	Neutral	89
Bijoy Telivala @BijoyTelivala	The curves initially cross and than separate out Is that due to initial increase toxicity with Cilta- Cel ?	Neutral	77
Victor H Jimenez-Zepeda @vhugo8762	P Vorhees takes the podium and talks on early relapse anti-BCMA strategies! #IMS2025	Neutral	65
Jeff Sharman @jeff_sharman	Thanks for the link: PFS also quite interesting. Early PFS events on cilta-cel largely didn't even make it to get experimental therapy in ITT analysis.... Longer follow up will be fascinating! Wonder if we might see a plateau???	Positive	60
chadi nabhan MD, MBA, FACP @chadinabhan	This week’s #HealthcareUnfiltered is out - all you need to know about multiple myeloma newest data from the latest Teo scientific congresses. #mmsm @bdermanmd of @UofC @UChicagoMed joins the show tackling all challenging questions in this …	Neutral	59

See full CARTITUDE-4 conference coverage & trial data →

Trial 2 · NCT03548207

What do oncologists think of the CARTITUDE-1 trial (CARVYKTI®)?

CARTITUDE-1 — Heavily pretreated relapsed/refractory multiple myeloma (single cilta-cel infusion after ≥3 prior lines / triple-class exposed)

FDA APPROVED · Feb 2022 · heavily pretreatedCARVYKTI® (ciltacabtagene autoleucel) received its original FDA approval (February 28, 2022) for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody — based on CARTITUDE-1.

Physicians are broadly favorable, with real nuance on CARTITUDE-1: 41% of 17 verified physician voices positive, 6% nuanced (praising the result while flagging a caveat), 53% neutral, 0% critical.

41%

53%

Positive 41% Nuanced 6% Neutral 53% Critical 0%

Denominator: 17 distinct verified physician voices across 62 oncologist posts, 2025-05-23 to 2025-06-15. Sponsor: Janssen Research & Development (with Legend Biotech)

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Primary sources: ClinicalTrials.gov · NCT03548207 · NCI Cancer Currents / FDA — CARVYKTI original R/R MM approval (Feb 2022)

FDA approval (February 28, 2022): ciltacabtagene autoleucel (CARVYKTI) for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy (based on CARTITUDE-1, NCT03548207).

Physician voices — verbatim

Representative positive voice

The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. @PlasmaCellPete @NoopurRajeMD @TomBmt133 @YiLinMDPhD @DMadduri

Vincent Rajkumar

@VincentRK

Representative nuanced voice

Median follow-up ~5 years! I am no expert in censoring unlike @Timothee_MD, but looking at the PFS K/M curve, its reassuring that most censoring after 60 months, as expected given the follow-up time (Not much early censoring 👍)!

Raj Chakraborty

@rajshekharucms

Full physician voice list (17)

Physician	Comment (verbatim)	Sentiment	Impressions
Vincent Rajkumar @VincentRK	The most impressive myeloma abstract at #ASCO25 Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50% 5 year PFS rate of 33% Astounding given multi-drug relapsed refractory setting. @PlasmaCellPete @NoopurRajeMD …	Positive	14,985
Ben Derman @bdermanmd	5-year PFS for cilta cel in CARTITUDE-1 was 33% ! Greater proportion of naive T cells in the product and higher CD4 central memory CAR+ T cell subsets at Cmax were associated with long term responders.	Neutral	5,687
Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1	The belle of the ball - long term follow up of CARTITUDE-1. One third rmeain alive and w/o progression at 5 years. 11 patients are MRD- at 10-6, possibly cured! (Denomitar varies if you substarct 5 patients lost to follow up or withdrew co…	Positive	5,261
Rahul Banerjee, MD, FACP @RahulBanerjeeMD	#ASCO25 And another one! @JCO_ASCO: 5-yr CARTITUDE-1 results for cilta-cel CAR-T. 97 pts, 6 prior #MMsm lines, treated 2018-2019. All likely would have died; instead, 1/3 alive & well 5 yrs out with no maintenance! 👏 Beginning of the end …	Positive	5,141
Nico Gagelmann @NicoGagelmann	Cilta-cel shows potential for CURE in RRMM❗️ In the CARTITUDE-1 trial, a single infusion of cilta-cel delivered remarkable long-term results in heavily pretreated patients with RRMM. After a median follow-up of 61 months, median overall …	Positive	2,896
Samer Al Hadidi, MD,MS,FACP @HadidiSamer	#mmsm #ASCO25 @JCO_ASCO Long term CARTITUDE-1 data published One out of 3 of patients treated with Cilta cel alive and disease free 5 years after ttt (tail of the curve)👇 Details of deaths 👇 and timing https://t.co/9A7Safq2mo	Positive	2,344
Al-Ola A Abdallah MD (USMIRC) @Abdallah81MD	A comparison of the CARTITUDE-1, LEGEND-2, and CARTIFAN-1 trials, along with insights from longer follow-up data. #mmsm #myeloma #MedEd #MedTwitter #USMIRC @USMIRCNEWS @OncoAlert #سرطان_الدم #المايلوما	Neutral	1,794
Taha A, MD @Taha_CancerDoc	If patients get 5+ years from their 1st transplant, many of us would recommend a 2nd transplant at relapse .. Do we do the same with long term #CARtcell responders in myeloma and do 2nd infusion? (If we can convince insurance to cover it an…	Neutral	1,530
Muzaffar Qazilbash @Transplant_Doc	#ASCO25 Long-term outcomes of CARTITUDE-1 (cilta-cel) in RRMM. N=97, median F/U: 60 months, 33% alive and progression-free, median OS: 60.6 months. Total 2nd heme malignancies: 10 (10.3%) #mmsm #bmtsm @PlasmaCellPete @TomBmt133	Neutral	1,289
Victor H Jimenez-Zepeda @vhugo8762	Cartitude-1 long term data as presented before! #eha2025	Neutral	530
Monzr M. AlMalki, MD @DrMonzrAlMalki	Excellent results- would be of interest to learn about 1 or 2 year therapy related mortality (i.e. died with no disease activity). Do we have access to this?	Neutral	435
Jim Omel @IMFjimMYELOMA	Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma \| Journal of Clinical Oncology https://t.co/uGlcfatZcQ Open Access.	Neutral	430
Raj Chakraborty @rajshekharucms	Median follow-up ~5 years! I am no expert in censoring unlike @Timothee_MD, but looking at the PFS K/M curve, its reassuring that most censoring after 60 months, as expected given the follow-up time (Not much early censoring 👍)!	Nuanced	329
Kunal Jobanputra MD, DM @KNJobanputra	CARTITUDE-1: Cilta-cel in RRMM (median previous lines of Rx : 6.5) #myeloma mFU 60.3 months. 33% (32/97) progression-free ≥5 years post-infusion. Biomarkers Higher naïve T cells lower neutrophil : T cell ratio higher Cmax : sBCMA More C…	Neutral	232
Yi Lin @YiLinMDPhD	Great job @Kennethjclim presenting @MayoCancerCare risk factor of IEC-nerve palsy & Parkinsonism #EHA25 #mmsm Hopefully we will learn soon from CARTITUDE trials & RWE across centers whether additional early mitigating strategies could redu…	Positive	208
Eduardo F O Ribeiro @EduardoFlavioO1	“From hospice to cure”- Dr Sundar Jagannath #EHA2025 Multiple Myeloma Relapse Refractory- CARTITUDE-1 Long Term 5y Follow Up	Neutral	86
Chenyu Lin, MD @ChenyuLinMD	Asking as a non-myeloma person, do we think this is a cure or just delaying relapse? Either way, great results.	Positive	79

Full conference coverage and trial data: KOL Pulse trial profile coming soon.

Regulatory

CARVYKTI® — FDA status

FDA APPROVEDCARVYKTI® (ciltacabtagene autoleucel) is an FDA-approved BCMA-directed CAR-T cell therapy for relapsed or refractory multiple myeloma — first approved February 28, 2022 for heavily pretreated disease, and expanded April 5, 2024 to earlier-line relapsed/refractory disease after at least one prior line. Developed and marketed by Johnson & Johnson (Janssen) and Legend Biotech. Carries FDA boxed warnings including cytokine release syndrome, neurologic toxicities, and secondary hematologic malignancies. For the full, current list of FDA indications and prescribing information, see carvykti.com or FDA label (DailyMed). KOL Pulse indexes the physician conversation; the label is owned and maintained by the manufacturer.

Frequently Asked

CARVYKTI® sentiment — FAQ

CARTITUDE-4

What do oncologists think of the CARTITUDE-4 trial (CARVYKTI®)?

Across 46 verified physician voices in KOL Pulse's index for CARTITUDE-4, 22% expressed positive sentiment, 24% were nuanced (praising the result while flagging a caveat), 45% were neutral, and 9% were critical. Positive voices highlight a single CAR-T infusion delivering deep, durable responses and a large progression-free-survival benefit over standard triplets — moving cilta-cel into earlier lines of relapsed/refractory myeloma; nuanced and critical voices flag the early deaths/early-progression signal in the first months, CAR-T toxicities (CRS, neurotoxicity, delayed neurologic events, secondary malignancies), and vein-to-vein access, manufacturing and bridging-therapy logistics.

Where can I find the CARTITUDE-4 trial data for CARVYKTI® (ciltacabtagene autoleucel)?

CARTITUDE-4 is registered as NCT04181827 and studied CARVYKTI® (ciltacabtagene autoleucel) in Earlier-line relapsed/refractory multiple myeloma (single cilta-cel infusion vs standard triplet regimens; 1–3 prior lines, lenalidomide-refractory). For the full CARTITUDE-4 trial data and conference coverage, see the KOL Pulse CARTITUDE-4 trial profile at kolpulse.com/kol-pulse-trial-profile-cartitude-4.

CARTITUDE-1

What do oncologists think of the CARTITUDE-1 trial (CARVYKTI®)?

Across 17 verified physician voices in KOL Pulse's index for CARTITUDE-1, 41% expressed positive sentiment, 6% were nuanced (praising the result while flagging a caveat), 53% were neutral, and 0% were critical. Positive voices highlight unprecedented depth and durability of response from a single infusion in patients who had exhausted standard options — establishing BCMA CAR-T as transformative in heavily pretreated myeloma; nuanced and critical voices flag CAR-T toxicities including delayed neurologic events (movement/neurocognitive, parkinsonism), secondary malignancies, and the access, cost and manufacturing barriers to delivering CAR-T.

Where can I find the CARTITUDE-1 trial data for CARVYKTI® (ciltacabtagene autoleucel)?

CARTITUDE-1 is registered as NCT03548207 and studied CARVYKTI® (ciltacabtagene autoleucel) in Heavily pretreated relapsed/refractory multiple myeloma (single cilta-cel infusion after ≥3 prior lines / triple-class exposed). KOL Pulse's CARTITUDE-1 trial profile is coming soon.

Regulatory

Is CARVYKTI® (ciltacabtagene autoleucel) FDA approved?

CARVYKTI® is FDA-approved. KOL Pulse organizes this page by clinical trial and links out to the manufacturer's brand site and the FDA label for the full, current list of FDA indications and prescribing information — the label is owned and updated by the manufacturer, so we point to it rather than reproducing it.

Methodology

How this index is built

KOL Pulse indexes verbatim posts from verified oncology physicians and rolls sentiment up per clinical trial. Each physician is counted once per trial, at their highest-reach post. Sentiment is classified from the verbatim text (positive / nuanced / neutral / critical), where "nuanced" marks a voice that praises the result while flagging a substantive caveat (immature overall survival, toxicity, or trial-design/selection concerns). Institutional, media, finance, and non-physician accounts are excluded from the denominator. Quotes are reproduced verbatim and attributed to the physician's public post. KOL Pulse organizes this page by clinical trial — the maintainable unit — and links out to the manufacturer's brand site and the FDA label for the full indication list, which the manufacturer owns and updates. Trial efficacy figures are held for medical-expert verification before publication. This page reports the physician conversation; it is not medical advice and does not endorse any product.